
APDN Stock Forecast & Price Target
APDN Analyst Ratings
Bulls say
Applied DNA Sciences Inc. anticipates significant revenue growth in the latter half of calendar 2024, primarily fueled by increased customer orders for critical mRNA therapeutic starting materials. The company has demonstrated consecutive quarterly revenue growth, with total revenue rising to $891 million in F1Q24, reflecting strong demand and the advancement of its first-phase GMP production slated for the first half of 2024. Additionally, the innovative Linea IVT platform enhances mRNA production efficiency and safety, positioning the company favorably within the biotechnology industry and supporting its commercial adoption.
Bears say
Applied DNA Sciences Inc. has experienced a significant downturn in its financial performance, reporting a total revenue of $0.8 million for F4Q23, which reflects a staggering 78% year-over-year decline. This continued decline in revenue, driven primarily by reductions in COVID-19 testing services and cotton DNA tagging revenue, indicates persistent challenges in its core business segments. Furthermore, the company reported a net loss of $3.6 million in F4Q23 and a total annual revenue of $13.4 million for FY2023, which marks a 26% year-over-year decline, compounding concerns about its growth strategy and operational progress amidst regulatory hurdles.
This aggregate rating is based on analysts' research of Applied DNA Sciences and is not a guaranteed prediction by Public.com or investment advice.
APDN Analyst Forecast & Price Prediction
Start investing in APDN
Order type
Buy in
Order amount
Est. shares
0 shares